|
|
Volumn 5, Issue 8, 2004, Pages 461-
|
|
Pegfilgrastim lowers side-effects of chemotherapy
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIINFECTIVE AGENT;
DOCETAXEL;
LONG ACTING DRUG;
PLACEBO;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
ANTINEOPLASTIC AGENT;
DRUG DERIVATIVE;
ADVANCED CANCER;
BREAST CANCER;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG HALF LIFE;
EVIDENCE BASED MEDICINE;
FEBRILE NEUTROPENIA;
FREQUENCY ANALYSIS;
HEMATOLOGIC DISEASE;
HIGH RISK PATIENT;
HOSPITALIZATION;
HUMAN;
INFECTION;
INFECTION RISK;
MAJOR CLINICAL STUDY;
MALIGNANT NEOPLASTIC DISEASE;
NOTE;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RISK REDUCTION;
SOLID TUMOR;
TREATMENT OUTCOME;
ARTICLE;
BREAST TUMOR;
CHEMICALLY INDUCED DISORDER;
FEMALE;
FEVER;
MULTICENTER STUDY;
NEUTROPENIA;
RISK FACTOR;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE III;
FEMALE;
FEVER;
FILGRASTIM;
HUMANS;
INFECTION;
MULTICENTER STUDIES;
NEUTROPENIA;
RANDOMIZED CONTROLLED TRIALS;
RISK FACTORS;
TREATMENT OUTCOME;
|
|
EID: 4043144984
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(04)01536-0 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|